Yanyun Hao, Hui Li, Xiaoyan Ge, Yang Liu, Jialin Yin, Xia Li, Yutong Liu, Hongfei Chen, Lingling Huang, Jing Zou, Shiying Zhang, Hao Wu, Zhiyue Zhang
Immunotherapy has fundamentally altered cancer treatment; however, its effectiveness is clinically hampered by insufficient intratumoral T lymphocyte infiltration and failed T lymphocyte priming. Additionally, inducing cancer-specific immune responses while sparing normal cells remains challenging. Herein, we developed a redox-activatable polymeric nanoswitch (c-N@IM/JQ) that remained 'off' status in circulation but rapidly switched 'on' after entering the tumor. Toll-like receptor (TLR) 7/8 agonist (imidazoquinoline, IMQ) and bromodomain and extraterminal inhibitor (JQ1) are locked in c-N@IM/JQ with a redox-cleavable linker (switch off)...
August 1, 2023: Journal of Controlled Release